January 12, 2011 -- LinkMed transplantation companies’ Olerup SSP and AbSorber has signed an exclusive
distribution agreement for the Brazilian market, the world's second largest transplantation
market after the US. Partner in Brazil is Genese Produtos Diagnosticos Ltda in Sao Paulo.
Genese Produtos Diagnosticos (Genese) is currently active in diagnostics, products for
laboratories, food testing and diagnostics in veterinary medicine. Genese is a well established
company with over 30 employees.
With this distribution agreement Genese will create a new division and allocate resources that
will become focused on the transplantation market. Personnel from Genese will undergo training
on the Olerup SSP and AbSorber's products in Sweden in February. Olerup SSP, as well as
AbSorber will apply for registration of their products at the Brazilian registration authority, the
National Health Surveillance Agency (Anvisa).
Brazil is a rapidly growing market with a state-controlled transplantation program. Some of the
world's largest transplantation centers are located in Brazil, where they conducted more than
5,000 kidney transplantations annually. The market is regionally concentrated in the southeast
around the cities of Sao Paulo and Rio de Janeiro where almost 80 percent of the clinics are
"Brazil will be one of the key markets for our transplantation business. We expect to launch our
products in 2011. Genese has been selected as the distributor since we believe is the best
partner for us, and we have high expectations for future sales success in Brazil, "says LinkMed’s
CEO Ingemar Lagerlöf.
For more information please contact:
Ingemar Lagerlöf, CEO, cell +46 (0) 70-873 2733 or email firstname.lastname@example.org
Or visit www.linkmed.se
LinkMed AB discloses the information provided herein pursuant to the Securities Markets Act and/or the
Financial Instruments Trading Act. The information was submitted for publication at 14:45 (CET) on January
LinkMed develops life science companies in collaboration with innovators and other financiers. By
contributing management and capital, LinkMed has created a portfolio of thirteen companies, four
in drug development and biotechnology and nine in diagnostics and medical technology. The
company’s principal shareholders are Mohammed Al Amoudi, FastPartner AB (publ), and
Mannersons Fastighets AB. LinkMed is listed on the NASDAQ OMX Stockholm Exchange in the
Small Cap section (ticker: LMED).